Don't Rely on Anti-Xa Levels to Verify LMWH Efficacy or Safety

We're getting questions about how to dose low-molecular-weight heparin (LMWH) for venous thromboembolism in obesity and renal impairment.

Dosing a LMWH (enoxaparin, etc) can be tricky in these cases. Usual doses may not be enough for obese patients...or they may accumulate and be too much for patients with renal impairment.

Obesity. For acute venous thromboembolism (VTE) treatment, dose LMWH based on ACTUAL body weight...even in patients over 150 kg.

Get unlimited access through an Enterprise license

Hospital Pharmacist's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Not sold to individuals